iobitridol has been researched along with Neuroendocrine Tumors in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Böning, G; Freyhardt, P; Kahn, JF; Kaul, D; Pavel, M; Rotzinger, R; Streitparth, F | 1 |
| Beiderwellen, KJ; Bockisch, A; Buchbender, C; Hartung-Knemeyer, V; Kuehl, H; Lauenstein, TC; Poeppel, TD | 1 |
2 other study(ies) available for iobitridol and Neuroendocrine Tumors
| Article | Year |
|---|---|
CT follow-up in patients with neuroendocrine tumors (NETs): combined radiation and contrast dose reduction.
Topics: Adult; Aged; Aged, 80 and over; Contrast Media; Female; Follow-Up Studies; Humans; Iohexol; Male; Middle Aged; Neuroendocrine Tumors; Radiation Dosage; Radiographic Image Interpretation, Computer-Assisted; Signal-To-Noise Ratio; Tomography, X-Ray Computed | 2018 |
Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
Topics: Adult; Aged; Contrast Media; Diagnosis, Differential; Female; Gallium Radioisotopes; Gastrointestinal Neoplasms; Gastrointestinal Tract; Humans; Image Enhancement; Iohexol; Magnetic Resonance Imaging; Male; Multimodal Imaging; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreas; Pancreatic Neoplasms; Pilot Projects; Positron-Emission Tomography; Prospective Studies; Reproducibility of Results; Tomography, X-Ray Computed; Whole Body Imaging | 2013 |